{Reference Type}: Journal Article
{Title}: Empagliflozin's role in early tubular protection for type 2 diabetes patients.
{Author}: Zhang C;Ren W;Lu X;Feng L;Li J;Zhu B;
{Journal}: Mol Med
{Volume}: 30
{Issue}: 1
{Year}: 2024 Jul 31
{Factor}: 6.376
{DOI}: 10.1186/s10020-024-00881-0
{Abstract}: <B>BACKGROUND: </B>Patients with type 2 diabetes often face early tubular injury, necessitating effective treatment strategies. This study aimed to evaluate the impact of the SGLT2 inhibitor empagliflozin on early tubular injury biomarkers in type 2 diabetes patients with normoalbuminuria.<BR><B>METHODS: </B>A randomized controlled clinical study comprising 54 patients selected based on specific criteria was conducted. Patients were divided into an intervention group (empagliflozin, n = 27) and a control group (n = 27) and treated for 6 weeks. Tubular injury biomarkers KIM-1 and NGAL were assessed pre- and post-treatment.<BR><B>RESULTS: </B>Both groups demonstrated comparable baseline characteristics. Post-treatment, fasting and postprandial blood glucose levels decreased similarly in both groups. The intervention group exhibited better improvements in total cholesterol, low-density lipoprotein, and blood uric acid levels. Renal function indicators, including UACR and eGFR, showed greater enhancements in the intervention group. Significant reductions in KIM-1 and NGAL were observed in the intervention group.<BR><B>CONCLUSIONS: </B>Treatment with empagliflozin in type 2 diabetes patients with normoalbuminuria led to a notable decrease in tubular injury biomarkers KIM-1 and NGAL. These findings highlight the potential of SGLT2 inhibitors in early tubular protection, offering a new therapeutic approach.